Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study J.E. Meca-Lallana; J.C. Álvarez-Cermeño; B. Casanova Estruch; G. Izquierdo Ayuso; R. Ortiz Castillo; A. Rodríguez-Antigüedad; C. Calles Hernández;

Pharmacogenetic studies in Alzheimer disease T. Zúñiga Santamaría; P. Yescas Gómez; I. Fricke Galindo; M. González González; A. Ortega Vázquez; M. López López;

Fear of Relapse Scale: Spanish version and psychometric characteristics in a sample of patients with Relapsing-Remitting multiple sclerosis Y. Broche-Pérez; R.M. Jiménez-Morales; L.O. Monasterio-Ramos; L.A. Vázquez-Gómez; Z. Fernández-Fleites;